A group of factors, such as gene expression, survival status, genetic alteration, tumor mutation burden (TMB), microsatellite instability (MSI), methyltransferases genes, immune infiltration, and relevant cellular pathway, are included to investigate the potential associations between CARM1 and the pathogenesis and clinical prognosis of different cancers, providing a basis for further understanding the role of CARM1 in tumor immunotherapy. The gene discussed is CARM1; the disease is neoplasm.